A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease

Leukemia. 2008 Aug;22(8):1613-6. doi: 10.1038/leu.2008.7. Epub 2008 Feb 7.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Amino Acid Sequence
  • CD4-Positive T-Lymphocytes / immunology
  • Cancer Vaccines / administration & dosage*
  • Cancer Vaccines / therapeutic use
  • Enzyme-Linked Immunosorbent Assay
  • Female
  • Fusion Proteins, bcr-abl / chemistry*
  • Humans
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / immunology
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
  • Male
  • Middle Aged
  • Molecular Sequence Data
  • Pilot Projects

Substances

  • Cancer Vaccines
  • Fusion Proteins, bcr-abl